Sildenafil citrate during labor did not improve perinatal outcomes potentially related to intrapartum hypoxia despite ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

Bristol-Myers Squibb (NYSE:BMY) recently announced a significant partnership with BioNTech SE to co-develop and ...

BioNTech SE's $11.1B oncology move signals potential, but clinical hurdles remain. Click for my look at the BNTX deal with ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

Among patients who received four-drug consolidation therapy, 84% had measurable residual disease (MRD)-negative status before ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company. With a market cap of ...

When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. | After ...

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.